Quince Therapeutics (QNCX) Interest Coverage Ratio (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Interest Coverage Ratio of 503.1 for Q1 2026, down 79.46% year-over-year from 2449.64 in Q1 2025, and down 50.78% quarter-over-quarter from 333.67 in Q4 2025.
Quince Therapeutics (QNCX) Interest Coverage Ratio (2018 - 2026) Analysis & Trends
Quince Therapeutics' Interest Coverage Ratio history runs 9 years deep, the most recent figure standing at 503.1 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 79.46% year-over-year to 503.1; the TTM figure through Mar 2026 stood at 0.98 (down 191.81% YoY), while the FY2025 annual figure was 0.68, down 9.02% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 503.1, down from 333.67 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 0.17 in Q4 2023, with the low at 503.1 in Q1 2026.
- The 5-year median for Interest Coverage Ratio is 15.45 (2024), against an average of 91.17.
- Peak annual rise in Interest Coverage Ratio reached 99.58% in 2025, while the deepest fall reached 1714.29% in 2025.
- Quince Therapeutics' Interest Coverage Ratio stood at 10.11 in 2022, then soared by 101.73% to 0.17 in 2023, then sank by 5233.76% to 8.95 in 2024, then plunged by 3627.71% to 333.67 in 2025, then tumbled by 50.78% to 503.1 in 2026.
- Business Quant data shows QNCX's Interest Coverage Ratio at 503.1 in Q1 2026, 333.67 in Q4 2025, and 104.92 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -503.10 |
| Dec 31, 2025 | -333.67 |
| Sep 30, 2025 | -104.92 |
| Jun 30, 2025 | -0.18 |
| Mar 31, 2025 | -280.34 |
| Sep 30, 2024 | -8.95 |
| Jun 30, 2024 | -42.27 |
| Mar 31, 2024 | -15.45 |
| Dec 31, 2023 | 0.17 |
| Sep 30, 2023 | -24.87 |
| Jun 30, 2023 | -6.86 |
| Mar 31, 2023 | -13.61 |
| Sep 30, 2022 | -10.11 |
| Jun 30, 2022 | -19.17 |
| Mar 31, 2022 | -4.18 |
| Dec 31, 2021 | -1.50 |
| Sep 30, 2021 | -15.81 |
| Jun 30, 2021 | -14.50 |
| Mar 31, 2021 | -62.00 |
| Dec 31, 2020 | -0.42 |